# BPC-157 TB-500 References: The Cited Preclinical and Regulatory Record

> BPC-157 TB-500 references — the full citation register behind this digest: peer-reviewed tendon, actin, angiogenesis, and ligament studies, recent reviews, and the FDA 503A compounding sources, with DOIs and PubMed links.

The complete citation list behind this digest — per-component preclinical studies, recent reviews, and the FDA compounding sources for the access record.

## How this register works

These are the [preclinical research citations](/references) and regulatory sources behind every quantitative claim on this site. Citations 1-13 cover the per-component preclinical and review literature on BPC-157 and TB-500 / Thymosin Beta-4. Citations 14-16 are the FDA sources behind the 503A compounding and access record on the legal-status page. Each entry carries a DOI or a PubMed/FDA URL so any claim can be traced to its source. Where a study used full-length Thymosin Beta-4 rather than the TB-500 7-mer, the digest says so — the identity distinction is part of the honest record.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110:774-780. https://pubmed.ncbi.nlm.nih.gov/21030672/
[6] Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38:716-725. https://pubmed.ncbi.nlm.nih.gov/18668315/
[7] Tokura Y, et al. Muscle injury-induced thymosin beta4 acts as a chemoattractant for myoblasts. J Biochem. 2011. https://pubmed.ncbi.nlm.nih.gov/20880960/
[8] Xiong Y, et al. Thymosin beta4 enhances the healing of medial collateral ligament injury in rats. Regul Pept. 2013. https://pubmed.ncbi.nlm.nih.gov/23523891/
[9] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[10] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[11] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[12] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[13] Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025. https://pubmed.ncbi.nlm.nih.gov/39861766/
[14] July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. Public calendar listing BPC-157 and TB-500 as bulk drug substances being considered for inclusion on the 503A Bulks List (scheduled discussion, not a decision). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
[15] Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration. Definitions of Category 1 and Category 2 and the 503A/503B compounding and bulks-list framework. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[16] Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. U.S. Food and Drug Administration. Category 2 entries for BPC-157 and for 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500,' effective with the September 29, 2023 update. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

---

Two repair signals tracked as two bands of cold light — BPC-157's green leg and TB-500's violet leg, each read against its own studies, the convergence left labeled theoretical and the FDA 503A status read first; no clinic behind the aurora and nothing here dispensed.